Alibaba Integrates Qianwen into Apple Intelligence
Prefer us on Google
Alibaba has announced that Qianwen will be integrated as an AI capability into Apple Intelligence, serving Chinese users on iOS, iPadOS, macOS, and visionOS. Users can directly experience Qianwen's text and image understanding, content generation, and other features on Apple devices without switching between applications.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like
Morning Report | Korea Investment & Securities and OKX plan to jointly acquire 40% of Coinone; Polymarket denies implementing KYC comprehensively; Grayscale delays U.S. stock IPO plans
Vitalik updates on CROPS AI progress: proposes combining private remote LLM calls with Ethereum private RPC reads
Tokenized US Stock Duel: Ondo vs. xStocks, Who is Defining On-Chain Nasdaq?
The BNB Chain MVB10 project BitRing is about to launch its genesis airdrop test and introduce the "fitness mining" mechanism
Visa Expands Stablecoin Support Across Four New Blockchains: A Game-Changer for Crypto Payments
Key Takeaways Visa is set to integrate support for four new stablecoins on four distinct blockchains, enhancing its…
Why Moderna (MRNA) Stock More Than Doubled: The INTerpath-001 Cancer Vaccine Result, Explained
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Web3: Foreign Media Reports that the Altcoin Market in 2026 May Depend on ISM Recovery
CoinFerenceX and the best event join forces to launch “CoinFerenceX The Best Event Singapore,” the decentralized summit
BCCC Introduces JPYC for Annual Membership Fee Payments
Modernizing Financial Infrastructure for Digital Assets by 2026
Web3: Foreign Media Reports Three Changes That May Boost SHIB
"I received an airdrop, but will I have to pay taxes next year?"... How to calculate in advance with a coin calculator
Critical Patch for Decred: Those Who Don't Update Risk a Network Fork
UnitedHealth Discloses Tax Dispute with the IRS
HeyBreez Raises $2.5 Million for Global Expansion in Voice AI
Web3 Wallets in a "Season of Turmoil": Understanding the Evolution of Crypto Security's "Sword and Shield" in the AI Era
Congress Members Raise Concerns Over AI Errors in New Legislation — Politico
Unitree Robotics Stock: How to Buy 688836 After Its 629% IPO Surge
DGrid AI: Reconstructing AI Infrastructure with On-Chain Verification and Open Markets
Ripple Prioritizes Institutional Financial Infrastructure Strategy Over IPO
Treasury Yields Surge to 5.3%, Hitting Tech Stocks WEEX TradFi Daily | Aug 19
Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.
ServiceNow Expands Security Portfolio with $7.75 Billion Acquisition
Ethereum’s 12-GPU proving problem just got a 4-GPU answer
How to Join WEEX 牛来 Airdrop: 50,000 USDT Rewards Guide
Fabrinet Earnings Beat Expectations: Why Did FN Stock Fall?
Non-consensus Decisions in the Robotics Sector: Why Sequoia Chose to Double Down on Yushu at Its Most Difficult Time?
牛来 Coin After the Rally: Opportunity or Meme Coin Risk?
AI: Five ECB Economists Consider a Correction of Tech Values Likely
Toyota Tokenized Bonds: Is 1 Billion Yen Finance Coming to Your Smartphone?
Is NEAR's trading volume at zero: can staking on NEAR Protocol revive it?
Morning Report | Korea Investment & Securities and OKX plan to jointly acquire 40% of Coinone; Polymarket denies implementing KYC comprehensively; Grayscale delays U.S. stock IPO plans
Vitalik updates on CROPS AI progress: proposes combining private remote LLM calls with Ethereum private RPC reads
Tokenized US Stock Duel: Ondo vs. xStocks, Who is Defining On-Chain Nasdaq?
The BNB Chain MVB10 project BitRing is about to launch its genesis airdrop test and introduce the "fitness mining" mechanism
Visa Expands Stablecoin Support Across Four New Blockchains: A Game-Changer for Crypto Payments
Key Takeaways Visa is set to integrate support for four new stablecoins on four distinct blockchains, enhancing its…
Why Moderna (MRNA) Stock More Than Doubled: The INTerpath-001 Cancer Vaccine Result, Explained
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
